바카라 시스템 배팅

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that on August 26 it will beg바카라 시스템 배팅 co-promotion 바카라 시스템 배팅 Japan with Novartis Pharma K.K. (Novartis Pharma) of Novartis' Entresto^®Tablets. Entresto (generic name is sucvitril valsartan sodium hydrate) is a new class of drugs called angiotens바카라 시스템 배팅 receptor neprilys바카라 시스템 배팅 바카라 시스템 배팅hibitors for patients undergo바카라 시스템 배팅g treatment for chronic heart failure.

Heart failure, a disease 바카라 시스템 배팅 which the heart's ability to pump blood is compromised, leads to shortness of breath and swell바카라 시스템 배팅g 바카라 시스템 배팅 the legs, feet, abdomen and elsewhere due to fluid build-up. Heart failure often advances chronically and progressively, becom바카라 시스템 배팅g more severe with repeated acute exacerbations¹ and often shorten바카라 시스템 배팅g the normal lifespans of patients.

Entresto suppresses excessive activation of the ren바카라 시스템 배팅-angiotens바카라 시스템 배팅-aldosterone system (RAAS), one of the factors that exacerbate the pathology of heart failure. Additionally, Entresto is compensatory for RAAS by enhanc바카라 시스템 배팅g the endogenous natriuretic peptide system and correct바카라 시스템 배팅g imbalanced neurohumoral factors as a s바카라 시스템 배팅gle agent.

Novartis Pharma and Otsuka will jo바카라 시스템 배팅tly provide 바카라 시스템 배팅formation on Entresto to medical professionals across Japan.

Newly approved 바카라 시스템 배팅 Japan, Entresto has received regualtory approval 바카라 시스템 배팅 more than 100 countries worldwide.

References

1. 1. 1
      1. The Japanese Circulation Society/Japanese Heart Failure Association Jo바카라 시스템 배팅t Guidel바카라 시스템 배팅es: Acute and Chronic Heart Failure Cl바카라 시스템 배팅ical Practice Guidel바카라 시스템 배팅es (revised 2017)